GlassScriptPhysician profile
Janet R Haskell
NPI 1750350062
$3,226.70
in general payments reported to CMS, 2019-2025
24 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.90 · 2022: $1,536 · 2023: $574 · 2024: $434 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,544.56 | 2022-2023 | Synchromedii, Intellis Adaptivestim |
| Abbvie INC. | $400.71 | 2021-2025 | |
| Ucb, INC. | $223.83 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Emd Serono, INC. | $176.04 | 2023-2025 | Mavenclad |
| Vanda Pharmaceuticals INC. | $122.03 | 2025 | Ponvory |
| Eisai INC. | $89.71 | 2023-2025 | |
| Argenx US, INC. | $87.60 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Mallinckrodt Hospital Products INC. | $76.93 | 2023-2025 | Acthar |
| Lilly USA, LLC | $59.80 | 2024-2025 | Kisunla, Amyvid |
| Neurocrine Biosciences, INC. | $55.93 | 2023-2024 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $42.97 | 2023-2024 | Ultomiris |
| Cycle Pharmaceuticals INC | $37.38 | 2025 | Bafiertam, Tascenso Odt |
| Catalyst Pharmaceuticals, INC. | $34.10 | 2024-2025 | |
| Axsome Therapeutics, INC. | $34.10 | 2025 | Symbravo, Sunosi |
| Jazz Pharmaceuticals INC. | $33.28 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $32.13 | 2025 | Tysabri, Vumerity |
| Kyowa Kirin, INC. | $31.86 | 2023-2024 | Nourianz |
| Lundbeck LLC | $31.21 | 2024 | Vyepti |
| Sk Life Science, INC. | $29.04 | 2025 | |
| Impel Pharmaceuticals INC. | $19.54 | 2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $18.53 | 2023 | Lyvispah |
| Tonix Medicines, INC. | $16.36 | 2025 | Zembrace Symtouch |
| Pfizer INC. | $14.75 | 2025 | |
| Merz Pharmaceuticals, LLC | $14.31 | 2025 | Xeomin, Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Haskell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.